Seven major health systems have invested in an initiative to create a nonprofit generic drug company to combat high drug prices and address hospital shortages of generic drugs, Fortune reported. Organizers last week announced that the initiative, Civica Rx, has received $30 million in funding from the health systems, which collectively represent more than 120 health organizations representing about one-third of U.S. hospitals. Among the health systems invested in Civica Rx are Denver-based Catholic Health Initiatives and Trinity Health of Livonia, Mich., the partner health systems of Des Moines-based Mercy Health Network. Martin VanTrieste, the former chief quality officer at biotech giant Amgen, will be Civica’s CEO. The nonprofit will initially focus on 14 specific generic drugs administered in hospitals that have been subject to shortages or exorbitant price increases.